Holen Sie sich die Stockscreener-App
8.02
0.62%
-0.05
Schlusskurs vom Vortag:
$8.07
Offen:
$8.055
24-Stunden-Volumen:
115.72K
Relative Volume:
1.11
Marktkapitalisierung:
$164.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+10.47%
1M Leistung:
+28.53%
6M Leistung:
-8.97%
1J Leistung:
+0.00%
1-Tages-Spanne:
$7.7601
$8.3305
1-Wochen-Bereich:
$6.8078
$8.43
52-Wochen-Spanne:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Firmenname
Actuate Therapeutics Inc
Sektor
Branche
Telefon
847-986-4190
Adresse
1751 RIVER RUN, FORT WORTH
Vergleichen Sie ACTU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.02 | 167.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-17 | Eingeleitet | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Aktie (ACTU) Neueste Nachrichten
Fermented Stevia Extract Shows Promise in Fighting Pancreatic Cancer in Lab Tests - AInvest
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - The Globe and Mail
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - The Globe and Mail
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - The Globe and Mail
What makes Actuate Therapeutics Inc. stock price move sharplyRSI and MACD Signal Summary with Trends - Newser
Has Actuate Therapeutics Inc. found a price floorLow Drawdown Stock Screener with Analysis - Newser
Actuate Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingInvestment Timing Strategy with Market Filters - Newser
Hillman Solutions Corp shares rise 3.41% intraday after Actuate Therapeutics announced a clinical trial collaboration with UPMC Hillman Cancer Center. - AInvest
Actuate Therapeutics to collaborate with Incyte Corporation on clinical trials - MarketScreener
Actuate Therapeutics To Collaborate with Incyte Corporation - GlobeNewswire
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - The Globe and Mail
Risk adjusted return profile for Actuate Therapeutics Inc. analyzedWatchlist Summary for Active Day Traders - Newser
Does Actuate Therapeutics Inc. fit your quant trading modelExit Strategy Guide With Risk Control Plan - Newser
Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc - Barchart.com
Candlestick Signal Suggests Reversal in Actuate Therapeutics Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru
What drives Actuate Therapeutics Inc. stock priceBuild wealth faster with consistent investment plans - Jammu Links News
Actuate Therapeutics Inc. Stock Analysis and ForecastBuild a diversified portfolio for steady growth - Jammu Links News
What is the dividend policy of Actuate Therapeutics Inc. stockAchieve consistent profits with proven strategies - Jammu Links News
Is Actuate Therapeutics Inc. a growth stock or a value stockFree Expert Stock Watchlist - Jammu Links News
Is it the right time to buy Actuate Therapeutics Inc. stockAchieve superior returns with professional insights - Jammu Links News
Is Actuate Therapeutics Inc. a good long term investmentCapitalize on fast-growing stocks today - Jammu Links News
What are analysts’ price targets for Actuate Therapeutics Inc. in the next 12 monthsSuperior portfolio returns - Jammu Links News
What catalysts could drive Actuate Therapeutics Inc. stock higher in 2025Invest confidently with real-time market updates - Jammu Links News
What MACD signals say about Actuate Therapeutics Inc.7-Day Equity Return Range Forecast Model - Newser
What are Actuate Therapeutics Inc. company’s key revenue driversInvest confidently with professional market insights - Jammu Links News
What is the risk reward ratio of investing in Actuate Therapeutics Inc. stock - Jammu Links News
How volatile is Actuate Therapeutics Inc. stock compared to the marketFree Buy/Sell Signal Notifications - Jammu Links News
How strong is Actuate Therapeutics Inc. company’s balance sheetCapitalize on strategic market trends - Jammu Links News
How does Actuate Therapeutics Inc. compare to its industry peersTriple-digit wealth increases - Jammu Links News
What the charts say about Actuate Therapeutics Inc. todayInvestment Timing Strategy with Market Filters - Newser
Tick level data insight on Actuate Therapeutics Inc. volatilityTrading Opportunities Forecast by AI Insight - Newser
LifeMD Appoints Shayna Webb Dray as COO - The Globe and Mail
Volatility clustering patterns for Actuate Therapeutics Inc.Free Intraday Trend Analysis for Fast Gains - Newser
Actuate Therapeutics Inc. Trading Near Value Zone — Recovery AheadWeekly Watchlist of High Movers Released - metal.it
How Actuate Therapeutics Inc. stock performs during market volatilitySmart Chart Forecasting with AI Algorithms - Newser
Can swing trading help recover from Actuate Therapeutics Inc. lossesFundamental + Technical Combined Watchlist - Newser
Why Actuate Therapeutics Inc. stock attracts strong analyst attentionFree Real Trader Watchlist of Hot Stocks - Newser
Actuate Therapeutics: Elraglusib Continues to Impress, FDA Type B Meeting on Horizon - AInvest
Actuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B Meeting - Seeking Alpha
Will Actuate Therapeutics Inc. stock split in the near futureSwing Entry Risk Mitigation with Chart Analysis - Newser
How many analysts rate Actuate Therapeutics Inc. as a “Buy”Retirement Planning Tips With Low Risk - Jammu Links News
Published on: 2025-07-28 19:11:05 - metal.it
Finanzdaten der Actuate Therapeutics Inc-Aktie (ACTU)
Es liegen keine Finanzdaten für Actuate Therapeutics Inc (ACTU) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
3.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):